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Abstract.  The distribution of human low density lipo- 
protein (LDL) receptors was studied by immunofluo- 
rescence and immunoelectron microscopy in epithelial 
cells of transgenic mice that express high levels of 
receptors under control of the metallothionein-I pro- 
moter. In hepatocytes and intestinal epithelial cells, 
the receptors were confined to the basal and baso- 
lateral surfaces, respectively. Very few LDL receptors 
were present in coated pits or intracellular vesicles. In 
striking contrast, in the epithelium of the renal tubule 
the receptors were present on the apical (lumenal) sur- 
face where they appeared to be concentrated at the 
base of microvilli and were abundant in vesicles of the 
endocytic recycling pathway. Intravenously ad- 
ministered LDL colloidal gold conjugates bound to the 
receptors on hepatocyte microvilli and were slowly in- 
ternalized, apparently through slow migration into 
coated pits.  We conclude that (a) sorting of LDL 
receptors to the surface of different epithelial cells 
varies with each tissue; and (b)  in addition to a  signal 
for clustering in coated pits, the LDL receptor may 
contain a  signal for retention in noncoated membrane 
that is manifest in hepatocytes and intestinal epithelial 
cells, but not in renal epithelial cells or cultured hu- 
man fibroblasts. 
T 
hE  low  density  lipoprotein  (LDL)  ~ receptor  binds 
cholesterol carrying lipoproteins and carries them into 
cells via endocytosis in coated pits (9). After discharg- 
ing its ligand in the endosome, the receptor returns to the 
surface. The steady-state distribution of LDL receptors has 
been studied by immunoelectron microscopy in human skin 
fibroblasts that were induced to produce large amounts of 
receptors (1). These fibroblasts have a smooth surface that 
is relatively free of microvilli. In the steady state '~70 % of 
the cell surface LDL receptors are located in coated pits, and 
the rest are found in small clusters that are randomly dis- 
tributed on the membrane. Receptors are also present in en- 
docytic vesicles, multivesicular bodies, and small recycling 
vesicles (22, 23). 
Indirect studies suggest that the steady-state distribution of 
receptors may be different on epithelial cells. Two types of 
epithelial cells have been studied by electron microscopy 
with  the  use  of  ~25I-LDL and  colloidal gold-LDL com- 
plexes.  In livers of rats with high level expression of LDL 
receptors induced by 17a-ethinyl estradiol, bound LDL is 
diffusely distributed on the microvilli of the sinusoidal (bas- 
al) surface (5, 11, 12, 13). A relatively small amount of LDL 
is visualized in coated pits. A similar finding was reported 
in cultured ovarian granulosa cells (21). In both liver (11, 12) 
and granulosa cells (21),  time course studies revealed that 
LDL-gold complexes are internalized through slow migra- 
tion from the microvillar surface into coated pits. 
1. Abbreviation  used in this paper:  LDL, low density lipoprotein. 
The previous  studies of hepatocytes used LDL-gold to 
mark cell surface LDL receptors, a method that cannot be 
used to study the localization of  receptors in membrane com- 
partments of fixed cells. In the past, it has not been possible 
to use immunoelectron microscopy for these measurements 
since the number of hepatic LDL receptors is less than the 
number on induced fibroblasts and is below the limits for re- 
liable quantitation. 
To circumvent this problem, in the current paper we have 
studied the distribution of LDL receptors in epithelial cells 
from organs of mice that express high levels of human LDL 
receptors encoded by a transgene (14). In epithelial cells of 
liver and small intestine, the vast bulk of receptors was dis- 
tributed  diffusely on  the  basal  and  basolateral  surfaces, 
respectively, and only a small number was visualized in en- 
docytic vesicles. In sharp contrast, in the epithelium of the 
renal tubule the expressed LDL receptors were found on the 
apical (lumenal) surface where they appeared to be concen- 
trated at the base of the microvilli. They were also abundant 
in endocytic vesicles. The data suggest that different polar- 
ized epithelial cells may sort LDL receptors differently and 
that a specific signal may be required to retain LDL recep- 
tors on the surface of liver and intestinal epithelial cells. 
Materials and Methods 
Materials 
Chemicals used for immunofluores,ence and electron microscopy were ob- 
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Figure 1. LDL receptor transgene 2. The promoter and transcrip- 
tion initiation sites derived from the mouse metallothionein-I gene 
are indicated by a striped box. LDL receptor e×ons are denoted by 
filled-in areas and introns by open areas. Vertical slashes in intron 
1 indicate a region where a portion of this intron was deleted. The 
exons are numbered above the diagram. Thin lines represent poly- 
linker sequences. Sequences from the 3' end of the human growth 
hormone gene containing signals for transcription termination and 
polyadenylation are indicated by a  stippled box. 
tained  from  previously  reported  sources  (15, 22).  We obtained rabbit 
anti-mouse IgG and goat anti-rabbit IgG labeled with FITC from Zymed 
Laboratories (San Francisco,  CA); sheep anti-rabbit IgG from Organon 
Teknika-Cappel  (Malvern, PA); monoclonal mouse antidinitrophenol IgG 
from Oxford Biomedical (Oxford, MI); and goat anti-rabbit  IgG conjugated 
to gold (10 nm) from Energy Sciences (Woburn, MA). A polyclonal rabbit 
IgG directed against the LDL receptor was prepared by immunizing a New 
Zealand white rabbit with purified bovine LDL receptor as previously de- 
scribed  (25).  Rabbit anti-human LDL  antiserum was  purchased  from 
Calbiochem-Behring Corp.  (San Diego,  CA),  and the IgG fraction was 
purified on a protein A Sepharose column. A nonimmune rabbit IgG was 
prepared as reported earlier (25). 
Preparation of  LDL-Gold Conjugate 
Colloidal  gold,  15 nm in diameter,  was prepared as previously  described 
(23).  The LDL-gold conjugate was made as follows: human plasma LDL 
(d 1.019-1.063 g/ml) (8) was loaded onto a PD-10 column (equilibrated in 
distilled water),  eluted with distilled  water, and adjusted to a protein con- 
centration of 1 mg/ml.  Multiple 10-ml aliquots  of colloidal gold (adjusted 
to pH 5.5 with 1% [wt/vol] potassium carbonate) were each incubated with 
100-120-#g LDL protein, pooled together in the presence of BSA at a final 
concentration of 0.01% (wt/vol), and centrifuged in 30-ml polysulfone tubes 
in a Ti 50 rotor (Beckman Instruments, Palo Alto, CA) at 12,000  rpm at 
40C for 40 rain. Virtually all of the conjugate from each 30-ml of starting 
material was recovered in a loose pellet of ,,00.25 ml. Several loose pellets 
were pooled, dialyzed against PBS, gel filtered over a PD-10 column equili- 
brated with PBS, and stored at 4°C. Before injection into mice, the conju- 
gate was warmed to 37°C, and BSA was added at a final concentration of 
0.2 % (wt/vol). Estimation of the protein concentration of LDL in the LDL- 
gold conjugate was based on a recovery of 85 % as determined by parallel 
incubations in which 125I-LDL of known specific  radioactivity was con- 
jngated to gold. 
Construction of  MetaUothionein Promoter-LDL 
Receptor Minigene Plasmid 
An expression plasmid containing the mouse metaUothionein-I  promoter 
fused to a hybrid human LDL receptor gene (designated transgene 2) was 
constructed by standard methods of genetic engineering (19), involving a 
total of nine intermediate plasmids.  The final insert (Fig.  1) was harbored 
in the pTZ18R vector (Pharmacia Fine Chemicals, Piscataway, NJ) and con- 
tained in the following linear order, 5'--3':1.7 kb of DNA corresponding to 
the 5'-flanking region of the mouse metallothionein-I gene (14); exon 1 of 
the LDL receptor gene; a truncated form of intron 1 of the LDL receptor 
gene from which sequences between an Rsa I site 77 nucleotides  3' of exon 
1 and an Eco RI site located 3.1 kb 5' of exon 2 (26) had been deleted; exons 
and introns 2-4 of the LDL receptor gene; a eDNA fragment corresponding 
to exons 5-18 of the LDL receptor (27); and sequences from the 3' end of 
the human growth hormone gene containing signals for transcription termi- 
nation and polyadenylation  (14). The length of the metallothionein pro- 
moter-LDL r~eptor minigene is ,o14.7 kb, and the ~tpected size of the cor- 
rectly processed rnRNA is 2.9' kb.  Not I sites at the 5' and 3' ends of the 
minigene were used to excise the DNA from the plasmid vector prior to 
microinjection into fertilized  mouse eggs. 
Transgenic Mice 
A total of 405 eggs were microinjected with transgene 2 and transferred into 
pseudopregnant females (3). Among the 58 offspring, 25 (43%) contained 
the transgene as determined by dot hybridization  of DNA obtained from tail 
homogenates.  These mice were subjected to a partial hepatectomy at "05-6 
wk of age. 15 of 24 founder mice produced mRNA derived from the trans- 
gene in the liver as determined by solution hybridization (18). Of these 15 
mice, 4 showed a chronic absence (<1 mg/dl) of apoprotein B-100 in plasma 
as measured by rocket immunoelectrophoresis (14). These four mice were 
bred to C57BI/6J x  SJL F1 mice, and lines of transgenic mice were estab- 
lished. Mice from one of these 4 lines expressing transgene 2 (line 192-2) 
were used in this study. The line of mice carrying transgene 1 (line 93-4) 
(14) was bred to homozygosity  with respect to the transgene and has been 
maintained in this state. Where indicated, mice (20-25 g body weight) were 
treated using one of two methods for induction of the metallothionein pro- 
rooter with zinc: either ZnSO4 (25 mM) in the drinking water for 7 d be- 
fore sacrifice,  or 5 mg/kg of ZnSO4 in 0.1 mi injected intraperitoneally 12 
and 6 h before sacrifice. 
Injection of  Mice with LDL and LDL-Gold 
Mice were anesthetized with sodium pentobarbital (90 mg/kg body weight) 
and injected intravenously  (0.15-0.2  ml/injection) via the external jugular 
vein with either human LDL (one injection, 0.5 mg protein) or LDL-gold 
(four injections,  0.3 nag protein for each injection at 15-min intervals)  as 
indicated in the figure legends. Body temperature of the animals was main- 
tained by keeping them on a warming tray throughout the experiment. The 
lipoproteins  were injected in PBS or 0.15 M sodium chloride containing 
0.2% (wt/vol) BSA. 
Immunofluorescence Microscopy 
Mice were anesthetized as described above and were perfused through the 
ascending aorta with 40 ml of Hanks balanced salt solution for 5 min to 
remove  blood.  Mice were then fixed by the perfusion of 60 ml of 3 % 
(wt/vol) paraformaldehyde  in 100 mM sodium phosphate buffer at pH 8.0 
containing 3 mM trinitrophenol, 4 mM KCI, and 2 mM MgC12 for 5 rain. 
Samples of liver, kidney, and jejunum were removed and fixed in a fixative 
containing 60% (vol/vol) methanol, 10% (vol/vol) glacial acetic acid, 30% 
(vol/vol) inhibisol (l,l,l-trichloroethane) for 24 h. Further processing of tis- 
sues, paraffin embedding, sectioning, and indirect immunofluorescence  was 
done as previously  described (15). Briefly, deparaffinized,  hydrated tissue 
sections were soaked in buffer A (20 mM Tris-chloride at pH 8.5, 200 mM 
NaC1, 0.1% [wt/vol] BSA, and 0.02%  [wt/vol]  sodium azide)  for 30 min 
after which the sections were incubated sequentially with antibodies as fol- 
lows: overnight incubation with 50 #g/ml of rabbit anti-human LDL IgG, 
anti-LDL receptor IgG, or a nonimmune IgG, followed by a 2-h incubation 
with 25 #g/ml affinity purified, goat anti-rabbit IgG conjugated to F1TC. 
After each incubation, sections were rinsed with buffer A three times for 
5 min. Finally, sections were rinsed in distilled water for 30 s before mount- 
ing  in  1,4-diazobicyclo(2.2.2)octane.  Sections  were  observed and pho- 
tographed  using  a  Zeiss  photomicroscope  III  with  appropriate  filter 
package. 
Figure 2.  Immunofluorescence localization of the human LDL receptor (A-C) or injected human LDL (D) in livers of zinc-treated (A) 
or untreated (C and D) transgenic mice and in a  zinc-treated normal mouse (B). Mice expressing transgene 2  (A) or normal mice (B) 
were injected with zinc intraperitoneally before the experiment. Liver samples were perfusion fixed and embedded in paraffin for immuno- 
staining as described in Materials and Methods. A  transgenic animal that was not injected with zinc (C and D), received an intravenous 
bolus of human LDL  (0.5 nag protein)  15 min before the liver was perfused,  fixed, and processed.  CE,  central vein. Bar,  10 #m. 
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2 were treated with zinc in drinking water as described in Materials and Methods. Tissue samples were prepared for immunogold labeling 
as described in Materials and Methods. (A) Overview ofa hepatocyte. E, endothelial cell; my, microvilli; cp, coated pit; L, lipoprotein-rich 
vesicles; M, mitochondria; RER, rough endoplasmic reticulum; G, Golgi apparatus.  (B) High magnification of basal surface (arrowhead), 
lateral surface (curved arrow), and canalicular surface (c) of hepatocyte.  (Straight arrows) coated vesicles. Bars, 0.3  ~m. 
Immunoelectron Microscopy 
Tissue samples from perfusion-fixed mice were dissected out and kept over- 
night in the perfusion fixative. Vibratome sections (60-80 pm thick) were 
prepared and washed in 100 mM sodium phosphate buffer, pH 7.8, contain- 
ing 50 mM ammonium chloride for 30 min and then transferred to buffer 
B (buffer A containing 0.05 % [wt/vol] saponin) for 1 h. All the primary anti- 
bodies,  rabbit  anti-human  LDL  IgG,  anti-LDL  receptor  IgG,  and  the 
nonimmune IgG,  were diluted in buffer B at a final concentration  of 50 
#g/ml. Groups of 6-8 sections were incubated overnight with each of the 
antibodies. This was followed by a 3-h incubation with 20/~g/ml of sheep 
anti-rabbit  IgG conjugated with dinitrophenol  in buffer B (22)~ Sections 
were washed after each incubation three times for 5 rain each in buffer B. 
After a final wash, sections were rinsed twice in 100 mM sodium phosphate 
The Journal of Cell Biology, Volume i 11,  1990  350 Figure 4.  Immunogold localization of the human LDL receptor (A) and injected human LDL (B) on the basal surface of hepatocytes of 
noninduced transgenic mice.  Liver samples from the same animal described in Fig.  2  (C and D) were processed to localize either LDL 
receptors (A) or LDL (B) by immunogold labeling. E, endothelial cell; ray, microvilli; arrows, coated pits or vesicles; arrowhead,  lateral 
surface.  Bars, 0.4 ~m. 
buffer (pH 7.8), and fixed with 1.33% (vol/vol)  glutaraidehyde  for 2 h in 
the same buffer. Tissue sections were postfixed  with 1% (wt/vol) osmium 
tetroxide in phosphate buffer, dehydrated, embedded in Epon, sectioned, 
and processed to localize  DNP groups by immunogold labeling as previ- 
ously described (15). 
Immunoblot Analysis 
Mouse tissues (0.5-t.1 g) were homogenized in a polytron homogenizer in 
5 vol (wt/vol) of buffer containing 20 mM Tris-chloride at pH 8.0, 1 mM 
CaCI2,  150 mM NaCI,  1 mM PMSF,  1 mM 1,10-phenanthroline,  0.1 mM 
Table L Distribution  of  LDL and LDL Receptors in Normal and Transgenic Mouse Liver 
Gold 
Induction  Intravenous  IgG for  Number of  Total t~m  Gold particles/  particles/t~m 
of receptors  injection  immunogold  coated pits  of coated  ~m of coated  noncoated 
Mouse  with ZnSO4  of LDL  labeling  counted  membrane  membrane (a)  membrane (b)  Ratio (b/a) 
Experiment A 
Normal  Yes  No  Anti-LDL receptor  106  42  0.14  (6)*  0.12  (15)*  - 
Transgenic  Yes  No  Nonirnmune  339  136  0.12 (16)  0.30 (46)  - 
Transgenic  Yes  No  Anti-LDL receptor  378  151  0.48 (73)  41.5  (4,860)  86 
Experiment B 
Transgenic  No  No  Anti-LDL  163  65  0.077 (5)  0.16 (17)  - 
Transgenic  No  No  Anti-LDL receptor  421  168  0.39 (66)  12.3  (1,591)  32 
Transgenic  No  Yes  Anti-LDL  411  164  0.82  (134)  12.0 (1,503)  15 
Transgenic  No  Yes  Anti-LDL receptor  138  55  0.73  (40)  12.9 (1,610)  18 
Treatment of mice, preparation of liver, and immunogold labeling were performed as indicated in the legends to Figs. 3 and 4. Random photographs were taken 
at a magnification of 9,000, and negatives were printed at a final magnification of 24,000. At least 50 different photographs were taken for each treatment. Coated 
pits/vesicles located <0.5 ~m from the bepatocyte basal surface membrane were identified on the basis of morphology. The linear membrane present in each com- 
partment was measured with a Map Measuring device (Swirl Handle "l~ype, Keuffel and Esser, Switzerland), and the gold particles over each portion of membrane 
were tabulated. 
* The total number of gold particles found in coated pits are shown in parentheses. 
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centrifuged at 470 g for 10 min at 4°C in a rotor (SA 600; Sorvall Co., 
Dupont, Wilmington, DE), and the supernatant was spun at 100,000 g in 
a rotor (TFT 65.13; Sorvall Co.) for 1 h. The pellet was resuspended with 
a 21-G needle in 1 ml of 125 mM Tris-maleate  at pH 6.0, 1 mM CaCI2, 160 
mM NaCI, and 1% (vol/vol)  Triton X-100 containing all of the above  pro- 
tease inhibitors. The suspension  was centrifuged  at 100,000 g for I h at 4"C 
in a rotor (TFT 65.13; Sorvall Co.). The supernatant was subjected to 7% 
SDS-PAGE  under nonreducing conditions and transferred  to nitrocellulose. 
After transfer the filters were incubated in 50 mM Tris-chloride  at pH 8, 
2 mM CaCI2, 80 mM NaCI, 5% (wt/vol) nonfat dry milk, 0.2% (vol/vol) 
NP-40, and 0.01% (vol/vol)  Antifoam  A emulsion for 1 h at room tempera- 
ture. Filters were  then incubated  with 5 ttg/ml  of polyclonal  rabbit  anti-LDL 
receptor IgG in the above  buffer  for 1 h at room  temperature. After two 15- 
min washes with the above buffer, the filters were incubated with 125I-ia- 
beled goat anti-rabbit IgG (5  x  106 cpm/ml; ,~7,000 cpm/ng) for 1 h at 
room temperature. After  two 15-min  washes, the filters  were  dried and sub- 
jected to autoradiography. 
Results 
We examined two lines of transgenic mice, each containing 
a  different  LDL  receptor  transgene.  One  line  expressing 
LDL receptor transgene 1 was previously described by Hof- 
mann et al.  (14).  LDL receptor transgene  1 contains  the 
mouse metallothionein-I promoter fused to the coding re- 
gion of the eDNA for the human  LDL receptor.  Marked 
overexpression is achieved through administration of cad- 
mium,  which  induces  the  metallothionein  promoter (14). 
During the early stages of the current study, we found that 
this transgene contained a single base insertion at nucleotide 
position 2,564.  The frameshift resulted in a change in the 
COOH-terminal five amino acids of the LDL receptor (glu- 
asp-asp-val-ala-stop) to gly-gly-stop. To he certain that this 
COOH-terminal mutation did not alter the distribution of the 
receptor, we made a second group of transgenic mice that ex- 
pressed the correct receptor sequence, designated transgene 
2  (Fig.  1).  Transgene 2 is a minigene of the LDL receptor 
that contains the promoter and transcription  initiation site 
derived from the mouse metallothionein-I gene, a portion of 
the LDL receptor gene (exons 1--4 and their corresponding 
introns), and the coding region of the LDL receptor eDNA 
containing exons 5-18. As will be described below, we found 
no differences in the function or in the cellular distribution 
of the human receptor encoded by transgenes  1 or 2. 
Liver 
Previous studies in mice expressing LDL receptor transgene 
1 showed that cadmium treatment stimulated expression of 
the human receptor in liver, and this led to the elimination 
of LDL from plasma (14). After cadmium treatment, hepato- 
cytes from these animals internalized large amounts of intra- 
venously injected  fluorescently labeled human  LDL (14). 
Fig. 2 shows the localization of human LDL receptors by in- 
direct immunofluorescence in the hepatocytes of mice that 
expressed transgene 2  and were injected  intraperitoneally 
with ZnSO4 to induce high levels of LDL receptors. Abun- 
dant immunostaining of receptors was found at the sinusoi- 
dal surface (Fig. 2 A). The intensity of the fluorescence sig- 
nal was uniform among all sinusoidal surfaces, including the 
surface of hepatocytes near the central vein. There was no 
indication  of antibody  binding  within  the  cell.  Receptors 
were not present on the  surface of endothelial  or Kupffer 
cells, and there was little or no activity in the portal triad. 
Even though  the  antireceptor IgG reacts with  the  mouse 
LDL receptor, the hepatocytes of normal animals treated in- 
traperitoneally with zinc did not stain, presumably because 
the number of receptors is relatively small (Fig. 2 B). In ad- 
dition, a nonimmune IgG did not stain hepatocytes of zinc- 
treated transgenic animals (data not shown). 
Founder mice expressing transgene 2 and mice from line 
192-2 used in this study had undetectable levels of plasma 
apo B-100 even in the absence of zinc induction  (data not 
shown), suggesting that the basal level of transgene expres- 
sion was sufficient to clear mouse LDL from the plasma. 
Fig. 2 (C and D) compare the distribution of the LDL recep- 
tor with the distribution of receptor bound human LDL in 
a noninduced transgenic animal that had received an intrave- 
nous injection of human LDL 15 min before removing the 
liver. The receptor and the LDL were both localized to the 
basal surface of the hepatocytes. Little if any intact immuno- 
reactive LDL was detected within the cell. 
The immunofluorescence images indicated that the LDL 
receptor in transgenic animals was preferentially located on 
the  basal  surface  (sinusoidal  surface)  of the  hepatocytes. 
Electron  microscopic  images  of the  receptor  distribution 
using indirect immunogold labeling confirmed this observa- 
tion (Fig. 3). Numerous gold particles were distributed over 
the basal surface of the hepatocytes of zinc-treated, trans- 
genie animals (Fig. 3 A). The amount of labeling diminished 
as the basal surface membrane merged with the lateral sur- 
face membrane (curved arrow, Fig. 3 B), and there was vir- 
tually no label on the canalicular (apical) membrane (c, Fig. 
3 B). At the basal surface, immunogold labeling was found 
on the microvilli and the intermicrovillus membrane (Fig. 3, 
A and B).  The density of labeling over clathrin-coated pits 
(cp, Fig. 3 A; straight arrows, Fig. 3 B) was reduced com- 
pared with the other portions of membrane (mv, Fig. 3 A; ar- 
rowhead,  Fig.  3  B).  Labeling  was  not  present  over  en- 
dothelial cells or Kupffer cells of transgenic animals (E, Fig. 
3 A). No label was present on the surface of hepatocytes from 
zinc-treated normal animals (data not shown). 
In noninduced transgenie mice hepatocytes express fewer 
human LDL receptors than they do after zinc induction.  To 
determine whether the receptor distribution was different at 
this  lower  level  of expression,  we  examined  noninduced 
livers by immunoelectron microscopy (Fig. 4 A). The distri- 
bution of receptors in the noninduced transgenic hepatocytes 
was similar to that in the zinc-treated animals.  There was 
Figure 5. Binding and internalization  of intravenously administered LDL-gold in hepatocytes and sinusoidal cells from transgenic (A-C) 
and nontransgenic (D) livers. Normal mice (D) or mice expressing transgene 2 that had been injected intraperitoneally  with zinc (A-C) 
were injected intravenously with human LDL-gold as described in Materials and Methods. At the end of 1 h, the livers were pcrfusion 
fixed and processed for electron microscopy. (,4) my, microvilli; arrows, coated pits. (B) arrows, coated pits; arrowheads, endocytic com- 
partments. (C) (7, Golgi complex; arrows, Golgi-associated vesicles containing LDL-gold. (D) L, lysosome; my, microvilli; arrows, coated 
pits. Bars, 0.5/~m. 
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mainder of the cell surface. Even in cells expressing only a 
few receptors, the receptors were preferentially located on 
the apex of the microvilli (my, Fig. 4 A). In the same experi- 
ment we used an anti-LDL antibody to determine the cellular 
distribution of injected human LDL (Fig. 4 B). This distri- 
bution was similar to the distribution of receptors. 
These qualitative observations were confirmed by quan- 
titative analysis (Table I). In experiment A, the anti-LDL 
receptor IgG showed little labeling of hepatocytes from non- 
transgenic mice treated with zinc. When liver sections from 
zinc-treated transgenic mice were incubated with anti-LDL 
receptor IgG, the density of labeling with gold particles was 
86  times greater over noncoated membranes  (41.5  parti- 
cles/#m) than over coated membranes (0.48 particlesd/zm). 
In experiment B, we analyzed the distribution of LDL and 
LDL receptors in noninduced transgenlc mice that express 
fewer LDL receptors. In these animals, the density of label- 
ing over noncoated membranes was reduced when compared 
with  the  noninduced  animals  (12.3  particles/#m  versus 
41.5), but the density of labeling in coated pits was nearly 
the same (0.39  versus 0.48).  Thus, in the noninduced ani- 
mals, the ratio of noncoated membrane labeling to coated 
membrane labeling was lower than that in the zinc-treated 
animal (32 versus 86), but there was still a marked prefer- 
ence  for  noncoated  membranes.  When  the  noninduced 
animals were injected with LDL, there was a slight increase 
in the labeling of coated pits with the anti-receptor IgG (0.73 
particles/#m versus 0.39).  Nevertheless,  the vast bulk of 
receptors  remained  outside  of coated  pits.  An  antibody 
against LDL gave a similar distribution to that seen with the 
anti-receptor antibody. 
There was little immunogold labeling of LDL receptors in 
intracellular,  vacuolar  compartments  of  the  zinc-treated 
transgenic liver (Fig. 3). Very few gold particles were found 
in morphologically identifiable endosomes, multivesicular 
bodies, lipoprotein-rich vacuoles (L, Fig. 3 A), lysosomes or 
Golgi apparatus (G, Fig. 3 A). Likewise, when we used im- 
munogold labeling to analyze the distribution of LDL in 
nontreated transgenic mice that had been perfused with hu- 
man LDL (Fig.  4  B),  there was  little immunodetectable 
LDL in endocytic compartments. 
To determine whether receptor-bound LDL was able to 
enter the hepatocyte, we injected LDL-gold intravenously 
into  normal  and  transgenic  mice  that  were  treated  in- 
traperitoneally with zinc. Each animal received four injec- 
tions of LDL-gold at 15 min intervals, after which the livers 
were fixed and processed for electron microscopy. In the 
transgenic mice most of the hepatocytes had numerous gold 
particles distributed over the basal surface (Fig. 5 A) with the 
highest concentration on the microvilli. Occasionally, one or 
two particles were found in coated pits, but the majority of 
the labeling mirrored the receptor distribution detected by 
immunogold (Fig. 3). Normal mice had a negligible amount 
of gold labeling on the hepatocyte .surface (Fig. 5 D).  Al- 
though most of the gold on the cell surface was on microvilli, 
transgenic hepatocytes did internalize LDL-gold. Gold par- 
tides were found in endosomes (arrowheads, Fig. 5 B) at 
different stages of maturation and in lysosome-like vesicles 
near the apical cell surface. In addition, vesicles associated 
with the trans-Golgi apparatus often contained gold particles 
(Fig. 5 C). None of  these compartments were labeled in nor- 
mal mice injected with LDL-gold. 
Occasionally, we observed a  hepatocyte that contained 
gold particles throughout the endoeytic pathway.  In these 
cells, gold was found in coated pits (arrows, Fig. 5 B), endo- 
somes, and other endocytic compartments. Such cells ap- 
peared to be taking up LDL-gold at discrete regions of the 
surface while other areas of the surface of the same cell were 
quiescent. 
The endothelial and Kupffer ceils lining the sinusoid also 
internalized LDL-gold (Fig. 5 D). This uptake was equal in 
the normal and transgenic animals, and therefore it was not 
mediated by the human LDL receptor. We saw little gold on 
the surface of Kuptfer cells, but large numbers of particles 
were found in lysosomes. 
Intestinal Absorptive Cells 
The  intestinal  absorptive  cells  from jejunum  in  zinc- 
treated transgenic animals expressed relatively high levels of 
LDL receptors (Fig. 6). Indirect immunofluorescence showed 
that receptors were confined to the basal (b, Fig. 6,4) and 
lateral surfaces of the cell; there was almost no staining of 
the apical surface (a,  Fig. 6 A).  Nonimmune IgG did not 
stain the same tissue sample (Fig. 6 B). These findings are 
similar to those reported by Fong et al. (7) who studied by 
light microscopy the immunoperoxidase distribution of LDL 
receptors in the jejunum of rats. By electron microscopy, im- 
munogold labeling was uniform over the convoluted, lateral 
cell surface and the basal surface (Fig. 6,  C, D, and E). 
Coated pits appeared to have the same density of gold parti- 
cles as the noncoated membrane (Fig.  6  C).  Sparse gold 
labeling of intracellular vacuoles was observed, and the api- 
cal microvillar surface of the cells was devoid of label (mv, 
Fig. 6 D). 
Kidney 
The cells lining the convoluted tubules of the kidney ex- 
pressed the transgene 2-encoded human LDL receptor. Both 
proximal and distal segments of the loop of Henley were 
positive by immunofluorescence (Fig. 7 A). In contrast to the 
distribution in liver and intestine, in the renal epithelium 
LDL receptors were preferentially located at the apical sur- 
face. The immunofluorescence pattern suggested that recep- 
tor was concentrated at the base of the microvilli. Moreover, 
Figure 6. Immunofluorescence  (A and B) and immunogold (C-E) localization of the human LDL receptor in intestinal absorptive cells 
(jejunum) of transgenic mice. Mice expressing transgene 2 were treated with zinc either orally (A-C, and E) or intraperitoneally (D). 
(A) Cross section of intestinal villi (I0 incubated with anti-LDL receptor IgG; a, apical cell surface; b, basal surface. (B) Cross section 
of intestinal villi incubated with nonimmune IgG. (C) Lateral surface near the base of two absorptive ceils; arrows, coated vesicles. (D) 
Apical and lateral surfaces of two absorptive cells; mv, microvilli; arrowheads, lateral plasma membrane. (E) High magnification view 
of lateral surface near the middle of two cells. Bars, (A and B) 10 #m; (C, D, and E) 0.4/zm. 
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expressing transgene 2 were treated orally with zinc before fixation and processed for immunofluorescence using anti-LDL receptor IgG. 
Arrows,  vesicles in apical cytoplasm. Bar, 10 ~m. 
many of the  cells  (arrowheads,  Fig.  7  A)  had prominent 
vacuolar staining in the apical cytoplasm. The same tissue 
incubated  with  a  nonimmune antibody did  not  show  any 
staining (data not shown).  No staining with the anti-LDL 
receptor antibody was seen in normal mouse kidneys (Fig. 
7 B). 
Fig. 8 A shows a cross section of  an entire kidney epithelial 
cell that was prepared for immunogold labeling of the LDL 
receptor. The apical surface contained most of  the gold parti- 
cles  with  the  highest  concentration  at  the  base  of  the 
microvilli (Fig. 8 B). The apical cytoplasm showed numer- 
ous labeled vesicles (Fig. 8, A, C, and D). Some vesicles had 
the morphology of  multivesicular bodies (Fig. 8 D), whereas 
others were tubular (Fig.  8 A) or vesicular-tubular (Fig.  8 
C). These morphologic features are characteristic of endo- 
some and receptor recycling compartments (20, 22, 23). A 
similar distribution of  LDL receptors was observed in a zinc- 
treated animal that expressed transgene 1 (data not shown). 
The finding of immunostalnable LDL receptors only on 
the lumenal surface of the renal tubule raised the possibility 
that the antibody was detecting fragments of  the receptor that 
had been shed from another tissue and had entered the glo- 
merular filtrate.  To rule out this  possibility,  we prepared 
homogenates from liver and kidney of a transgenic mouse, 
subjected them to SDS gel electrophoresis and immunoblot 
analysis, and stained the proteins with an anti-LDL receptor 
antibody, which was visualized by autoradiography (Fig. 9). 
After a 2-h exposure, there was faint immunostaining of the 
LDL receptor in normal mouse liver (Fig. 9, lane 3) and an 
intense band in liver membranes from the transgenic mouse 
(Fig. 9, lane 5). After a prolonged 18-h exposure the LDL 
receptor in transgenlc mouse kidney was visualized as an in- 
tense band (Fig. 9, lane 9), which was much more intense 
than the band in normal mouse kidney (Fig. 9, lane 7). The 
transgene-encoded human receptor from liver and kidney 
migrated slightly slower than the mouse receptor, and the 
Figure 8. Immunogold localization of the human LDL receptor in kidney epithelial cells of transgenic mice. (A) Low magnification view 
of epithelial cell; BL, basal lamina; M, mitochondria; arrows,  coated pit or vesicle; arrowhead, tubular endosome; open arrows,  lateral 
plasma membrane. (B) High magnification view of apical surface of epithelial cell surface; mv, microvilli; arrow, coated vesicle. (C and 
D) High magnification views of endosomal compartments. Animals expressing transgene 2 were treated with zinc either orally (C) or in- 
traperitoneally (A, B, and D) before processing for immtmogold localization. Bars, 0.2 #m. 
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ney and liver of transgenic mice. Normal mice and mice expressing 
transgene 2 were treated with zinc intraperitoneally. Aliquots of  the 
100,000 g membrane fraction from liver and kidney (lanes 2 and 
4, 80 #g protein; lanes 3 and 5, 180/zg protein) were prepared as 
described in Materials and Methods, subjected to SDS-PAGE, and 
transferred to nitrocellulose filters. The filters were immunoblotted 
with  a  polyclonal  rabbit  anti-bovine  LDL  receptor  antibody, 
probed with a  l:~I-labeled goat anti-rabbit  IgG, and exposed to 
XAR-5 film with an intensifying screen at -70°C for either 2 h (A) 
or  18 h  (B).  Lane  1 contained 200 #g protein of a detergent- 
solubilized whole cell extract of CHO cells transfected with a plas- 
mid encoding the human LDL receptor cDNA (6). 
mobility of the human receptor in kidney was identical to 
that in liver. There was no evidence for an immunoreactive 
receptor fragment in the transgenic mouse kidney. 
Discussion 
The current immunocytochemical studies in transgenic mice 
have revealed differential sorting  of the  LDL receptor in 
different epithelial cells. In hepatocytes and intestinal epithe- 
lium,  the human LDL receptors were distributed diffusely 
on the basal and basolateral surfaces, respectively, and were 
observed only rarely in coated pits and endosomes. In con- 
trast, in renal tubular epithelium, the LDL receptors were 
preferentially located at the base of microvilli on the apical 
(lumenal)  surface and appeared frequently in endosomes, 
suggesting that they were actively engaged in endocytosis. 
The diffuse distribution of LDL receptors on microvilli of 
liver cells stands in marked contrast to their distribution in 
cultured fibroblasts (1) and fibroblast-like Chinese hamster 
ceils (6) where the bulk of receptors are located in coated 
pits and in membranes of the endocytic recycling pathway. 
The current findings are in agreement, however, with studies 
that have shown a diffuse, microvillar distribution of receptor- 
bound LDL-gold complexes in perfused livers from estra- 
diol-treated rats (11, 12) and in cultured rat ovarian granulosa 
cells (21). In both of these studies, the LDL-gold complexes 
appeared to move slowly to the base of the microvilli and 
were then internalized by coated pits. These findings imply 
that the transgene-encoded receptors must also move to coat- 
ed pits as they deliver LDL into the cell. In prior experi- 
ments,  we demonstrated uptake of intravenously adminis- 
tered fluorescently labeled LDL into hepatocytes (14), and, 
in the current experiments, we observed abundant internali- 
zation of gold-labeled LDL in the transgenic mouse livers. 
This uptake was far greater than was observed in the livers 
of nontransgenic animals, indicating that it was mediated by 
the human LDL receptor. Moreover, animals that received 
LDL displayed a slight increase (twofold) in the density of 
LDL receptors over coated pits (Table I), raising the possi- 
bility that LDL binding might accelerate this movement. 
Coated pit-mediated internalization of hepatic LDL recep- 
tors is also suggested by the metabolic abnormality in three 
human  subjects  with  the  internalization-defective form of 
familial  hypercholesterolemia  (6,  17).  These  individuals 
have mutations in the cytoplasmic domain of  the LDL recep- 
tor that prevent the receptor from moving into coated pits 
and from carrying bound LDL into the cell. Despite the nor- 
mal ability of these receptors to bind LDL, individuals with 
these mutations have plasma LDL levels that are as high as 
those found in individuals with absent receptors (10). Since 
the plasma LDL level is controlled largely by LDL receptors 
in the liver (4), the data indicate that internalization defective 
receptors do not function in liver and imply that normal LDL 
receptors function in liver cells by moving into coated pits. 
A  major question raised by our studies  is  whether the 
diffuse distribution of  LDL receptors in hepatocytes is a con- 
sequence of the saturation of coated pit binding sites, owing 
to the high level of receptor expression. Two observations 
suggest that this is not the case. First, lowering receptor con- 
centration by omitting treatment with zinc did not change the 
diffuse distribution. Second, despite the high receptor den- 
sity  on  the  uncoated  membrane  of  zinc-treated  animals 
(41.5//~m),  the density of receptors in coated pits was only 
0.48/#m (Table I). In human fibroblasts, receptor density in 
coated pits is 20/#m (22), suggesting that the liver coated pits 
are not saturated with LDL receptors. We cannot rule out 
the possibility that in hepatocytes coated pits are saturated 
with other receptors such as the asialoglycoprotein receptor. 
This would imply that the other receptors bind to coated pits 
with higher affinity than do LDL receptors. At present, there 
is no evidence to support this conclusion. We prefer the hy- 
pothesis that the movement of LDL receptors from micro- 
villi to coated pits is a regulated event and that liver cells have 
the capacity to retain LDL receptors for a prolonged time 
on the microvillar surface, admitting them to coated pits only 
slowly. 
In contrast to the results in liver, the appearance of LDL 
receptors on the apical  surface of renal tubular  epithelial 
ceils was unexpected. Biochemical assays do not detect large 
numbers of LDL receptors in kidney membrane prepara- 
tions (16). Moreover, we did not detect any endogenous LDL 
receptor either by immunogold or immunofluorescence la- 
beling techniques.  Therefore, we are unable to relate our 
findings in the kidney of  the transgenic mouse to the distribu- 
tion of the endogenous receptor in this tissue. Nevertheless, 
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apical surface, in contrast to its sorting to the basal surface 
in liver and basolateral surface in intestine, raises the possi- 
bility that renal  tubular epithelial cells may have a mecha- 
nism for apical sorting that differs from the mechanism in 
other epithelia. 
Our current understanding  of protein sorting in polarized 
epithelial  cells  is  largely  derived  from studies  of MDCK 
cells in vitro (24) and hepatocytes  in vivo (2).  Whereas in 
rat hepatocytes proteins destined for the apical surface are 
first directed to the basal surface (2), in the MDCK cells api- 
cal proteins are delivered directly to the apical surface (24). 
Further studies with LDL receptors containing various mu- 
tations in their cytoplasmic or extracellular domains should 
help to clarify the mechanism for this interesting  tissue-spe- 
cific sorting. 
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